$14.87
$0.46 (+3.19%)
$14.67Day Range$15.56
Key Statistics
Market Cap
$1.87B
Shares Outstanding
129.9M
Primary Exchange
XNAS
Currency
USD
Type
ADRC
IPO Date
Jan 5, 2009
Round Lot
100
Locale
US
Trading Data
Day Open
$14.77
Day High
$15.56
Day Low
$14.67
Volume
143.7K
VWAP
$14.89
Prev Close
$14.41
Transactions
--
Acc. Volume
--
About Mesoblast Limited American Depositary Shares
Mesoblast Ltd is a commercial-stage biotechnology company engaged in developing and commercializing allogeneic (off-the-shelf) cellular medicines for severe inflammatory conditions. Its commercial product, Ryoncil (remestemcel-L-rknd), is FDA-approved for steroid-refractory acute graft-versus-host disease in pediatric patients. The company is also developing Ryoncil for additional inflammatory indications. Its rexlemestrocel-L platform is being developed for chronic low back pain associated with degenerative disc disease and chronic heart failure. The company operates as a single segment focused on its allogeneic cellular medicines platform.
Identifiers
- CIK
- 0001345099
- Composite FIGI
- BBG000QD6LZ1
- Share Class FIGI
- BBG001SMNB80
- Ticker Root
- MESO
About Mesoblast Limited American Depositary Shares (MESO) Stock
Mesoblast Limited American Depositary Shares (MESO) closed the 2026-09-17 session at $14.87, up 3.19% versus the previous close (+0.46). The stock opened at $14.77 and traded between $14.67 and $15.56 during that session. Session trading volume was 144K shares. The volume-weighted average price (VWAP) is $14.89.
Mesoblast Ltd is a commercial-stage biotechnology company engaged in developing and commercializing allogeneic (off-the-shelf) cellular medicines for severe inflammatory conditions. Its commercial product, Ryoncil (remestemcel-L-rknd), is FDA-approved for steroid-refractory acute graft-versus-host disease in pediatric patients. The company is also developing Ryoncil for additional inflammatory indications. Its rexlemestrocel-L platform is being developed for chronic low back pain associated with degenerative disc disease and chronic heart failure. The company operates as a single segment focused on its allogeneic cellular medicines platform.
Mesoblast Limited American Depositary Shares has a market capitalization of $1.87 billion. MESO is listed on the XNAS exchange. The company employs approximately 108 people. The recorded listing date is 2009-01-05.
On this page you can find market MESO stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors.